Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Microbiome research: Link between gut bacterium and obesity and diabetes revealed


News provided by

Noster Inc.

30 Aug, 2022, 11:03 GMT

Share this article

Share toX

Share this article

Share toX

KYOTO, Japan, Aug. 30, 2022 /PRNewswire/ -- A collaboration between researchers at the National Institutes of Biomedical Innovation, Health and Nutrition, Noster Inc., and institutions throughout Japan has found that the bacterium Blautia wexlerae inhibits obesity and type 2 diabetes. The results are reported in Nature Communications. The finding may lead to the development of novel therapeutic strategies for these and related metabolic disorders.

This image opens in the lightbox
BMI-related and type 2 diabetes-related bacteria in Japanese adults.

Obesity is a major public-health issue, partly because its role in type 2 diabetes, caused by overnutrition, genetic background and environmental factors. One such factor is the set of microorganisms in a person's stomach known as the gut microbiota. These can produce substances that promote obesity or type 2 diabetes, but can also produce molecules that have anti-obesity or anti-diabetes properties. It is known that the gut microbiota is different for people from different geographical regions, because of differences in diets and genetic histories. It is also known that people with type 2 diabetes and obese persons have an altered gut microbiota composition. The Japanese diet in particular is unique, and the gut microbiome of Japanese people shows high abundance of Blautia bacteria. At the same time, Japanese people have the highest average life span worldwide, as well as a very low body­ mass index (BMI). Jun Kunisawa from the National Institutes of Biomedical Innovation, Health and Nutrition, and collaborators at Noster Inc., and research institutes throughout Japan have now investigated the link between the presence of Blautia bacteria and obesity and type 2 diabetes, and have revealed an inverse correlation.

A statistical analysis of the gut bacteria of 217 Japanese adults showed that Blautia bacteria are less abundant for obese (defined as having a BMI of 25 kg/m² or higher) people and for people with type 2 diabetes. The researchers checked that other factors such as age, sex and medication do not influence the proportion of Blautia in the gut.

Kunisawa and colleagues then analyzed which species of the Blautia genus are inversely correlated with obesity and type 2 diabetes. They found that the abundance of the Blautia wexlerae species was almost equal to that of Blautia overall.

The finding regarding Blautia wexlerae suggested that the gut bacterium might ameliorate obesity and type 2 diabetes. The scientists therefore studied the effect of administering the bacterium to mice that had been on a high-fat diet inducing obesity and diabetes. The bodyweight gain of the mice was suppressed, and Kunisawa and colleagues found that it also had inhibitory effects on diabetes. An analysis of the chemical processes taking place showed that Blautia wexlerae contains various small biomolecules (called metabolites) that have anti-inflammatory properties and promote energy metabolism.

Kunisawa and colleagues point out that whether Blautia wexlerae reduces obesity and diabetes in humans remains unclear — follow-up studies are needed. Nevertheless, quoting the scientists, "the discovery of a metabolic role of the gut microbiota in the pathophysiology of obesity and type 2 diabetes mellitus reveals opportunities for the development of preventive methods … and therapeutic approaches for metabolic disorders."

Background

Obesity and type 2 diabetes

Obesity refers to the condition of abnormal or excess body fat having extensively accumulated in such a way that it can have a negative effect on health. Obesity is usually defined via the body mass index (BMI, a person's weight divided by the person's height squared). Some definitions of obesity use a BMI of 30 kg/m² as the threshold, others use a BMI of 25 kg/m² as the starting point.

Obesity is correlated with several other conditions and diseases, including type 2 diabetes. The latter is a form of diabetes characterized by a high blood sugar, insulin resistance, and a relative lack of insulin. The long-term complications of type 2 diabetes include heart disease, strokes, and kidney failure. Type 2 diabetes mainly occurs as a result of obesity and insufficient physical exercise.

The combination of obesity and type 2 diabetes is sometimes called 'diabesity'. Factors that can lead to diabesity include genetic history, diet, lack of exercise and gut health.

The role of gut bacteria has now been studied by Jun Kunisawa from the National Institutes of Biomedical Innovation, Health and Nutrition, Noster, and colleagues at other research institutes in Japan. Starting from the notion that Japanese people have a high life expectancy, a low BMI, and a particular diet, they looked for inverse correlations between particular gut bacteria and obesity and type 2 diabetes. They identified Blautia wexlerae as a gut bacterium that likely ameliorates obesity and type 2 diabetes. 

Reference

Koji Hosomi, Mayu Saito, Jonguk Park, Haruka Murakami, Naoko Shibata, Masahiro Ando, Takahiro Nagatake, Kana Konishi, Harumi Ohno, Kumpei Tanisawa, Attayeb Mohsen, Yi-An Chen, Hitoshi Kawashima, Yayoi Natsume-Kitatani, Yoshimasa Oka, Hidenori Shimizu, Mari Furuta, Yoko Tojima, Kento Sawane, Azusa Saika, Saki Kondo, Yasunori Yonejima, Haruko Takeyama, Akira Matsutani, KenjiMizuguchi, Motohiko Miyachi, and Jun Kunisawa. Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota, Nature Communications 13, 4477 (2022).

DOI: 10.1038/s41467-022-32015-7
URL: https://www.nature.com/articles/s41467-022-32015-7

Contact details

Noster Inc., International Relations,
35-3 Minamibiraki, Kamiueno-cho,
Muko-shi, Kyoto, 617-0006, Japan

E-Mail: contact@noster.inc
Telephone: 81 (0)-75-921-5303

Noster
Noster Inc. website
https://www.noster.inc/

Noster's analytical services
https://www.noster.inc/services/

Photo: https://mma.prnewswire.com/media/1887908/Noster_Inc_BMI_related.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.